Abstract
Prader-Willi syndrome is a rare genetic disorder characterized by hypotonia, poor feeding in infancy, hyperphagia with evolving obesity, hypogonadism, decreased adult height, and cognitive and behavioral disabilities.Recombinant human growth hormone (rhGH) has been used in treating Prader-Willi syndrome, and it has achieved good results.Several aspects still need to be concerned, including evaluation before rhGH treatment, age at treatment initiation, dosing, monitoring of potential side effects, tolerability, endpoint, response evaluation, use of adjunct therapies, and issues of consent. Key words: Prader-Willi syndrome; Recombinant human growth hormone; Insulin-like growth factor-1; Obesity; Metabolic syndrome
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
